Company: LIMN
Filing Date: 2025-01-27
Form Type: POS AM
Source: 0001104659-25-006325
Chunk: 231

Company: Liminatus Pharma, Inc.
Filing Date: 2025-01-27
Form: POS AM
Chunk 231
---
 to the Warrant Amendment, Iris will assign all of its right, title and interest in and to the Warrant Agreement to ParentCo. The Warrant Amendment also amends the Warrant Agreement such that, among other things, (i) all references to Iris in the Warrant Agreement (including all exhibits thereto) shall be references to ParentCo; and (ii) all references to “Common Stock” in the Warrant Agreement (including all exhibits thereto) shall be references to shares of ParentCo Common Stock. The Warrant Amendment also amends the notice provisions of the Warrant Agreement to contemplate notice to ParentCo under such agreement.

From and after the Effective Time, each whole warrant will entitle the registered holder to purchase one share of ParentCo Common Stock at a price of $11.50 per share, subject to adjustment as discussed below, at any time commencing on the later of 30 days after the completion of the Business Combination, except as described below.

See “ Description of ParentCo Capital Stock — Warrants — Public Warrants ” for a further description of the Warrant Amendment.

#### Regulatory Approvals
The Business Combination and the transactions contemplated by the Business Combination Agreement are not subject to any additional regulatory requirement or approval, except for filings required with the SEC pursuant to the reporting requirements applicable to Iris, and the requirements of the Securities Act and the Exchange Act, including the requirement to file the registration statement of which this proxy statement/ prospectus forms a part and to disseminate it to its stockholders.

### Background of the Business Combination
Iris (formerly known as Tribe Capital Growth Corp I) is a blank check company formed as a corporation in Delaware on November 5, 2020 for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. For purposes of this section, “Tribe Capital Growth” refers to Iris prior to its management and name change that occurred on or about July 27, 2022, as described in the section titled “ Iris’s Management’s Discussion And Analysis Of Financial Condition And Results Of Operations — Overview” in this proxy statement/ prospectus .

The Business Combination with Liminatus is the result of an extensive search for a potential initial business combination, whereby Iris evaluated a large number of potential targets utilizing the investing, operating and transaction experience of Iris’s management team, advisory partners and the Iris Board. The terms of the Business Combination are the result of arm’s-length negotiations between